|
gptkbp:instanceOf
|
gptkb:drug
|
|
gptkbp:approvalYear
|
2018
|
|
gptkbp:approvedBy
|
gptkb:PMDA
gptkb:FDA
gptkb:EMA
|
|
gptkbp:ATCCode
|
L01ED10
|
|
gptkbp:brand
|
gptkb:Lorbrena
gptkb:Lorviqua
|
|
gptkbp:CASNumber
|
1454846-35-5
|
|
gptkbp:chemicalFormula
|
C21H19FN6O2
|
|
gptkbp:developedBy
|
gptkb:Pfizer
|
|
gptkbp:eliminationHalfLife
|
20.6 hours
|
|
gptkbp:genericName
|
gptkb:lorlatinib
|
|
gptkbp:indication
|
gptkb:non-small_cell_lung_cancer
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
ALK inhibitor
ROS1 inhibitor
|
|
gptkbp:metabolism
|
gptkb:CYP3A4
|
|
gptkbp:molecularWeight
|
406.42 g/mol
|
|
gptkbp:pregnancyCategory
|
Not assigned
|
|
gptkbp:prescribes
|
ALK-positive metastatic non-small cell lung cancer
ROS1-positive metastatic non-small cell lung cancer
|
|
gptkbp:proteinBinding
|
66%
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
gptkb:peripheral_neuropathy
gptkb:familial_hypercholesterolemia
gptkb:interstitial_lung_disease
edema
hypertension
weight gain
QT prolongation
hepatotoxicity
cognitive effects
arthralgia
hypertriglyceridemia
mood effects
|
|
gptkbp:bfsParent
|
gptkb:lorlatinib
gptkb:923950-08-7
gptkb:Lorlatinib
|
|
gptkbp:bfsLayer
|
7
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Lorbrena
|